<b>Encapsulation of 5-fluorouracil in liposomes for topical administration</b> - DOI: 10.4025/actascitechnol.v25i1.2240
Abstract
This work aims to compare different methodologies for the preparation of dipalmitoylphosphatidylcholine/cholesterol (DPPC/Chol) liposomes entrapping the anticancer agent 5-fluorouracil (5-FU), a drug usually employed in melanoma therapy, designed for topical administration. The lipid vesicles were produced by dry lipid film hydration followed by extrusion, by ethanol injection and by reverse phase evaporation, while 5-FU was passively or actively incorporated into the liposomes. The results demonstrated that vesicle loading and stability can be controlled by the experimental procedure used to entrap the drug. Different initial drug to lipid molar ratios strongly affect encapsulation efficiency. The reverse-phase evaporation method resulted in the largest 5-FU encapsulation efficiency, around 6%. The preparation of these vesicles did not result in detectable drug degradation. During 4 weeks, no aggregation of liposomes was observed, however, extensive drug leakage from the vesicles was noticed.Downloads
Download data is not yet available.
Published
2008-04-15
How to Cite
Costa, C. A. M. da, & Moraes, Ângela M. (2008). <b>Encapsulation of 5-fluorouracil in liposomes for topical administration</b> - DOI: 10.4025/actascitechnol.v25i1.2240. Acta Scientiarum. Technology, 25(1), 53-61. https://doi.org/10.4025/actascitechnol.v25i1.2240
Issue
Section
Chemical Engineering
DECLARATION OF ORIGINALITY AND COPYRIGHTS
I Declare that current article is original and has not been submitted for publication, in part or in whole, to any other national or international journal.
The copyrights belong exclusively to the authors. Published content is licensed under Creative Commons Attribution 3.0 (CC BY 3.0) guidelines, which allows sharing (copy and distribution of the material in any medium or format) and adaptation (remix, transform, and build upon the material) for any purpose, even commercially, under the terms of attribution.
Read this link for further information on how to use CC BY 3.0 properly.
0.8
2019CiteScore
36th percentile
Powered by
0.8
2019CiteScore
36th percentile
Powered by